ABINGDON HEALTH PLC Logo

ABINGDON HEALTH PLC

A CDMO specializing in lateral flow assays, offering development to manufacturing services.

ABDX | IL

Overview

Corporate Details

ISIN(s):
GB00BLB79S77 (+2 more)
LEI:
213800XFI4WV3FBILO20
Country:
United Kingdom
Address:
YORK BIOTECH CAMPUS, YO41 1LZ YORK

Description

Abingdon Health PLC is a contract development and manufacturing organization (CDMO) that specializes in lateral flow assays, also known as rapid tests. The company provides a comprehensive, fully integrated service to a global customer base, supporting diagnostic projects from initial concept and development through to high-volume automated manufacturing and regulatory support. Its services cater to a wide range of sectors, including clinical, animal health, environmental, and plant health. Abingdon Health also develops and manufactures lateral flow readers and smartphone reader applications, which complement its assay services by enabling digital data capture and analysis.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-29 15:50
Exercise of options and total voting rights
English 16.0 KB
2025-12-18 08:25
European patent for AppDx® smartphone reader
English 15.7 KB
2025-12-10 15:00
Result of Annual General Meeting
English 14.5 KB
2025-12-04 08:45
Vesting and Award of Options under LTIP
English 87.4 KB
2025-12-02 16:20
Holding(s) in Company
English 119.0 KB
2025-11-14 15:10
Notice of AGM & Publication of 2025 Annual Report
English 15.7 KB
2025-11-11 08:20
Final Results
English 305.0 KB
2025-11-10 08:10
c.US$2m multiplex diagnostic test contract win
English 17.6 KB
2025-11-06 08:30
Launch of seaweed-based lateral flow housings
English 22.3 KB
2025-11-04 18:10
Holding(s) in Company
English 50.5 KB
2025-11-04 08:25
Holding(s) in Company
English 52.1 KB
2025-11-03 08:30
Notice of Results
English 17.3 KB
2025-10-30 10:43
Result of Meeting and TVR
English 61.1 KB
2025-10-17 08:00
Result of Retail Offer
English 24.5 KB
2025-10-14 08:58
Launch of Retail Offer
English 50.1 KB

Automate Your Workflow. Get a real-time feed of all ABINGDON HEALTH PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ABINGDON HEALTH PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ABINGDON HEALTH PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Entero Therapeutics, Inc. Logo
Clinical-stage biopharma developing oral therapies for gastrointestinal diseases.
United States of America
ENTO
Entrada Therapeutics, Inc. Logo
Clinical-stage biopharma developing EEV-based therapies for rare diseases.
United States of America
TRDA
Develops small molecule therapeutics for cancer, inflammation, and respiratory diseases.
South Korea
183490
Enzymatica AB Logo
Develops medical devices for infections based on a proprietary marine enzyme technology.
Sweden
ENZY
Epitomee Medical Ltd. Logo
Develops ingestible therapeutic devices for chronic diseases.
Israel
EPIT
EQL Pharma AB Logo
Develops and sells niche generic and specialty medicines, primarily in Nordic markets.
Sweden
EQL
Erasca, Inc. Logo
A clinical-stage oncology company developing therapies for RAS/MAPK pathway-driven cancers.
United States of America
ERAS
Ernexa Therapeutics Inc. Logo
Biopharmaceutical company developing cell therapies for cancer and autoimmune diseases.
United States of America
ERNA
ERYTECH Pharma S.A. Logo
Develops red blood cell-based therapies for cancer and orphan diseases.
France
ERYP
Esperion Therapeutics, Inc. Logo
Develops and commercializes oral medicines to reduce cardiovascular risk.
United States of America
ESPR

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.